These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33671700)

  • 1. Next Generation Sequencing for HIV-1 Drug Resistance Testing-A Special Issue Walkthrough.
    Kantor R
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33671700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations.
    Ávila-Ríos S; Parkin N; Swanstrom R; Paredes R; Shafer R; Ji H; Kantor R
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32516949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
    Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
    J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
    [No Abstract]   [Full Text] [Related]  

  • 4. Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework.
    Capina R; Li K; Kearney L; Vandamme AM; Harrigan PR; Van Laethem K
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32545906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 6. Update of the drug resistance mutations in HIV-1: December 2009.
    Johnson VA; Brun-Vezinet F; Clotet B; Gunthard HF; Kuritzkes DR; Pillay D; Schapiro JM; Richman DD
    Top HIV Med; 2009 Dec; 17(5):138-45. PubMed ID: 20068260
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessments of HIV drug resistance mutations in resource-limited settings.
    Jordan MR
    Clin Infect Dis; 2011 Apr; 52(8):1058-60. PubMed ID: 21460325
    [No Abstract]   [Full Text] [Related]  

  • 8. CODEHOP-Mediated PCR Improves HIV-1 Genotyping and Detection of Variants by MinION Sequencing.
    Sarkhouh H; Chehadeh W
    Microbiol Spectr; 2021 Oct; 9(2):e0143221. PubMed ID: 34668751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detecting primary drug-resistant mutations in Korean HIV patients using ultradeep pyrosequencing.
    Cho MC; Park CW; Park BG; Oh HB; Choi SH; Choi SE; Cho NS
    J Virol Methods; 2016 Aug; 234():115-22. PubMed ID: 27109046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2011 update of the drug resistance mutations in HIV-1.
    Johnson VA; Calvez V; Günthard HF; Paredes R; Pillay D; Shafer R; Wensing AM; Richman DD
    Top Antivir Med; 2011 Nov; 19(4):156-64. PubMed ID: 22156218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of gag mutations associated with in vitro resistance to capsid inhibitor GS-CA1 in HIV-1 antiretroviral-naive patients.
    Perrier M; Bertine M; Le Hingrat Q; Joly V; Visseaux B; Collin G; Landman R; Yazdanpanah Y; Descamps D; Charpentier C
    J Antimicrob Chemother; 2017 Oct; 72(10):2954-2955. PubMed ID: 29091184
    [No Abstract]   [Full Text] [Related]  

  • 13. External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges.
    Lee ER; Gao F; Sandstrom P; Ji H
    Viruses; 2020 May; 12(5):. PubMed ID: 32429382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.
    Reigadas S; Marcelin AG; Houssaïni A; Yerly S; Descamps D; Plantier JC; Ruffault A; Amiel C; Trabaud MA; Flandre P; Fleury H; Masquelier B;
    J Antimicrob Chemother; 2013 Apr; 68(4):969-72. PubMed ID: 23184711
    [No Abstract]   [Full Text] [Related]  

  • 15. Description of two commercially available assays for genotyping of HIV-1.
    Stürmer M; Reinheimer C
    Intervirology; 2012; 55(2):134-7. PubMed ID: 22286883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and Application of Performance Assessment Criteria for Next-Generation Sequencing-Based HIV Drug Resistance Assays.
    Becker MG; Liang D; Cooper B; Le Y; Taylor T; Lee ER; Wu S; Sandstrom P; Ji H
    Viruses; 2020 Jun; 12(6):. PubMed ID: 32532083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep Sequencing of HIV-1 in Cerebrospinal Fluid.
    Tong CY; Costelloe S; Hubb J; Mullen J; O'Shea S; Marta M; Kulasegaram R; Rackstraw S
    Clin Infect Dis; 2015 Sep; 61(6):1022-5. PubMed ID: 26021989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation sequencing improves detection of drug resistance mutations in infants after PMTCT failure.
    Fisher RG; Smith DM; Murrell B; Slabbert R; Kirby BM; Edson C; Cotton MF; Haubrich RH; Kosakovsky Pond SL; Van Zyl GU
    J Clin Virol; 2015 Jan; 62():48-53. PubMed ID: 25542470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine drug resistance testing in HIV-1 proviral DNA, using an automated next- generation sequencing assay.
    Alidjinou EK; Coulon P; Hallaert C; Robineau O; Meybeck A; Huleux T; Ajana F; Hober D; Bocket L
    J Clin Virol; 2019 Dec; 121():104207. PubMed ID: 31707202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.